Urban Wealth Management’s Stealth BioTherapeutics Corp. ADS MITO Stock Holding History

Urban Wealth Management’s Portfolio MITO Stock Details MITO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$1K	Buy	+2,939	New	+$1.01K	﹤0.01%	339

Other funds holding MITO

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Urban Wealth Management's MITO Position: Q2 2022 in Review

Urban Wealth Management opened a new position in Stealth BioTherapeutics Corp. ADS (MITO) in Q2 2022: 2,939 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #339 among its holdings.

19 funds tracked by Wall St. Rank hold MITO as of Q2 2022.

Urban Wealth Management held 2,939 shares of Stealth BioTherapeutics Corp. ADS worth $1K as of Q2 2022.
Stealth BioTherapeutics Corp. ADS was a new Urban Wealth Management position in Q2 2022.
Stealth BioTherapeutics Corp. ADS made up ﹤0.01% of Urban Wealth Management's portfolio in Q2 2022, its #339 holding.
19 funds tracked by Wall St. Rank held Stealth BioTherapeutics Corp. ADS as of Q2 2022.

Based on Urban Wealth Management's 13F filing for Q2 2022, filed 22 Jul 2022.